GLP-1 Agonists For Obesity Weight loss medications are approved for adults with obesity (BMI of 30 kg/m2 or more) or overweight (BMI of 27 kg/m2 or more) with a weight-related comorbidity, including high blood pressure, type 2 diabetes, or high cholesterol
Treatment goals: what is the BP goal
[12] The most noteworthy effect of GLP-1 is its ability to promote insulin secretion in a glucose-dependent manner
For a full overview of retatrutides mechanism, clinical trial data, dosage reference, and comparison with tirzepatide, see our Retatrutide Peptide Research Guide
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro
Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy